just the shorters again - usual play - won't stop till we aren't seen as exposed in relation to revenue streams (but who's listening??) - all IMO.
Get used to it - need to ignore SP and hope the dividends stack up here. Anyhow long term signs of weakness may be perceived by the market as other pharmaceuticals appear to be overtaking us with their technology. all IMO.
Add to My Watchlist
What is My Watchlist?
